U.S. markets closed

LivaNova PLC (LIVN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
58.05+2.30 (+4.13%)
At close: 04:00PM EST
58.05 0.00 (0.00%)
After hours: 04:01PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close55.75
Bid41.03 x 800
Ask73.17 x 800
Day's Range56.21 - 58.07
52 Week Range41.82 - 88.00
Avg. Volume412,088
Market Cap3.107B
Beta (5Y Monthly)0.83
PE Ratio (TTM)N/A
EPS (TTM)-1.97
Earnings DateFeb 22, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est72.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for LIVN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • LivaNova PLC
    LIVN: Raising target price to $59.00LIVANOVA PLC has an Investment Rating of HOLD; a target price of $59.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • Business Wire

    LivaNova Launches SenTiva DUO

    LONDON, February 02, 2023--LivaNova launched SenTiva DUO™, an implantable pulse generator with a dual-pin header to provide VNS Therapy™ for drug-resistant epilepsy treatment.

  • Reuters

    CORRECTED-FDA classifies recall of LivaNova's blood-pumping system controller as most serious

    The U.S. Food and Drug Administration on Friday classified the recall of LivaNova's device that controls a blood-pumping system at its most serious type, citing that their use could cause serious injuries or death. The medical device company recalled 589 units of the LifeSPARC system's controller, through the period of Dec. 19, 2019 to Nov. 17, 2022, for a software update to address a previously known malfunction. The controller's software malfunction may trigger the device to enter critical failure mode causing the pump to stop for an extended time period, the FDA said, which may lead to serious injury or death of the patient.

  • Business Wire

    LivaNova to Announce Fourth-Quarter and Full-Year 2022 Results

    LONDON, January 18, 2023--LivaNova PLC will host a conference call to discuss its fourth-quarter and full-year 2022 results on Feb. 22, 2023 at 1 p.m. London time (8 a.m. ET).